Cargando…
COVID-19 convalescent plasma
As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were limited treatment options and no prophylactic therapies for those exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma is quick to implement, potentially provides benefits...
Autores principales: | Tobian, Aaron A. R., Cohn, Claudia S., Shaz, Beth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548835/ https://www.ncbi.nlm.nih.gov/pubmed/34695186 http://dx.doi.org/10.1182/blood.2021012248 |
Ejemplares similares
-
Vasculopathy in COVID-19
por: Flaumenhaft, Robert, et al.
Publicado: (2022) -
Clinical features of thrombosis and bleeding in COVID-19
por: Thomas, Mari R., et al.
Publicado: (2022) -
COVID-19 in patients with hematologic malignancy
por: Langerbeins, Petra, et al.
Publicado: (2022) -
Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
por: Conway, Susan R., et al.
Publicado: (2022) -
Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020)